Triple-negative breast cancer (TNBC) is a kind of breast cancer that lacks estrogen,
progesterone, and human epidermal growth factor receptor 2. This cancer is responsible for …

Among different types of breast cancers (BC), triple-negative BC (TNBC) amounts to 15% to
20% of breast malignancies. Three principal characteristics of TNBC cells are (i) extreme …

Abstract The Cancer Genome Atlas (TCGA) is one of the largest biorepositories of digital
histology. Deep learning (DL) models have been trained on TCGA to predict numerous …

Importance Given conflicting results regarding the prognosis of erb-b2 receptor tyrosine
kinase 2 (ERBB2; formerly HER2 or HER2/neu)–low breast cancer, a large-scale, nationally …

Opinion statement In approximately 15–20% of the patients diagnosed with breast cancer, it
comprises the triple negative (TN) subtype, which until recently lacked targets for specific …

In the western world, breast cancer is the most common lethal cancer in women and the
second leading cause of cancer death behind lung cancer. 1 The American Cancer Society …

Triple negative breast cancer (TNBC) is a biologically diverse subtype of breast cancer
characterized by genomic and transcriptional heterogeneity and exhibiting aggressive …

Purpose Immunotherapy has started to transform the treatment of triple-negative breast
cancer (TNBC), in part due to the unique immunogenicity of this breast cancer subtype. This …

Long-standing scarcity of efficacious treatments and tumor heterogeneity have contributed to
triple-negative breast cancer (TNBC), a subtype with a poor prognosis and aggressive …

Aberrant tumor metabolic activities not only promote the aggressiveness and proliferation of
tumor cells in the harsh microenvironment in vivo, but also contribute to immune cell …